

Measuring blood pressure and cardiovascular risk in rural Kenya and The Gambia

Submission date 23/02/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 27/02/2024	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/02/2024	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Many people live with high blood pressure in sub-Saharan Africa. In this region, the proportion of people with high blood pressure is one of the highest in the world. However, few people with high blood pressure are treated and this can lead to serious medical issues and even death. This is particularly true in rural areas where treatment and understanding of blood pressure is lower than in cities.

There are many reasons why high blood pressure is a major health problem in rural sub-Saharan Africa, such as a lack of clear symptoms; less access to healthcare; and limited time to travel to clinics for care. One option for improving the management of blood pressure is to use a community-centred approach, where care is brought into the community making it easier to access.

To bring care into the community, we need to find out what is the best way for community health workers to identify who needs to be treated. Standard techniques may not be useful in a rural community and could require too many resources to make them practical. This study aims to determine what is the best way to identify high blood pressure and related health complications in a community setting.

Who can participate?

The study will take place across two sites: one in Kilifi, Kenya and the other in Kiang West, The Gambia. We will enrol 1250 participants, aged 30 years or older, with 625 in each country.

What does the study involve?

Participants who join the study will complete a series of short questionnaires about their general health status. They will then receive 4 different blood pressure measurements over a two-week period. These include a home-based measurement (twice daily for seven days), unattended and attended measurement (once each for 15 minutes) and a 24-hour measurement (the participants will wear a cuff for 24 hours). The blood pressure measurements will be conducted in a different order for each participant. Following the blood pressure measurements, the participants will attend their local clinical facility for tests to determine if they have any organ damage caused by high blood pressure. The tests will look at your heart,

eyes, kidneys, and blood vessels. A single blood draw is required. These tests will require two visits from the participant to the clinic facility. Any relevant findings will be reported back to the participant. After this, participants have completed their involvement in the study.

What are the possible benefits and risks of participating?

Benefits. Participants will have their blood pressure measured and be told whether they have high blood pressure. In addition, participants will be able to find out whether the high blood pressure has affected their organs. After the study, those with high blood pressure will be referred to the appropriate clinics for further care. There is a benefit to society by helping us find the best ways to measure blood pressure and associated organ damage.

Risks: The overall risk profile of this study is very low. Minor risks involved in participating in this study include loss of time completing blood pressure assessments and questionnaires.

Additionally, when invited to the hospital for further tests, participants will spend time travelling to the hospital and having the measurements. Participants will be compensated for their travel costs. Finally, there is risk of pain, redness, swelling or infection at the site of the blood draw.

Where is the study run from?

London School of Hygiene & Tropical Medicine (UK)

When is the study starting and how long is it expected to run for?

August 2022 to January 2026

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

ihcor_africa@lshtm.ac.uk

Contact information

Type(s)

Public, Scientific

Contact name

Mr Alexander Perkins

ORCID ID

<https://orcid.org/0000-0002-9817-2390>

Contact details

London School of Hygiene & Tropical Medicine, Keppel Street

London

United Kingdom

WC1E7HT

+44 20 7927 2723

IHCoR_Africa@LSHTM.ac.uk

Type(s)

Principal investigator

Contact name

Prof Pablo Perel

Contact details

London School of Hygiene & Tropical Medicine, Keppel Street
London
United Kingdom
WC1E7HT
+44 20 7927 2723
IHCoR_Africa@LSHTM.ac.uk

Type(s)

Principal investigator

Contact name

Prof Anthony Etyang

Contact details

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine
Kilifi
Kenya
P.O. Box 230-80108
+44 20 7927 2723
IHCoR_Africa@LSHTM.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Determining the optimal diagnostic and risk stratification approaches for people with hypertension in two rural populations in Kenya and The Gambia

Acronym

IHCoR-Africa WP2

Study objectives

Sub-Saharan Africa (SSA) has one of the highest prevalences of hypertension worldwide. The impact of hypertension is of particular concern in rural SSA, where access to clinics and hospitals is limited. Improvements in the management of people with hypertension in rural SSA could be achieved by shifting diagnosis and care from the clinic to the community. To develop such a

community-centred programme we need optimal approaches to identify and risk stratify patients with elevated blood pressure. The aim of the study is to improve the evidence base for diagnosis and risk estimation for a community-centred hypertension programme in two rural settings in SSA.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 06/03/2023, London School of Hygiene & Tropical Medicine Ethics Committee (Keppel Street, London, WC1E 7HT, United Kingdom; +44 20 7927 2723; ethics@LSHTM.ac.uk), ref: 28276
2. approved 06/02/2023, KEMRI Scientific & Ethics Review Unit (Center for Geographic Medicine Research, Coast, Kilifi, P.O. Box 230-80108, Kenya; +254 020 2722541; ddr@kemri.go.ke), ref: KEMRI/SERU/CGMR-C/277/4620
3. approved 06/03/2023, MRC the Gambia Ethics Committee (Atlantic Boulevard, Fajara, PO Box 273, Gambia; +220 44954426 Ext 2308; ethics@mrc.gm), ref: 28276

Study design

Multicentre cross-sectional cohort study

Primary study design

Observational

Study type(s)

Diagnostic, Prevention, Screening

Health condition(s) or problem(s) studied

Hypertension

Interventions

Participants will be identified through demographic surveillance systems and approached to participate. Those who consent will be entered into the study. Participants will have their blood pressure measured in four different ways over two weeks. These assessments include:

1. Attended and unattended Automated Blood Pressure Measurements (aABPM and uABPM), which take 10-15 minutes to conduct, will be performed at the homes of study participants
2. Home-based Blood Pressure Measurement (HBPM) which consist of morning and evening measurements performed by the individual participant for 7 days in a row
3. 24-hour ambulatory BP measurement (24-hr-ABPM) which requires participants to wear a blood pressure monitor for 24-hours.

After the blood pressure measurements, participants will be invited for two clinic visits to assess the impact of the hypertension on their heart, eyes, kidneys and blood vessels. They will receive electrocardiograms, echocardiography, blood tests, and diagnostic imaging of their retina. At these visits information will be collected on demographics, household assets, anthropometrics, diet, physical activity, history of hypertension and medication use. After the clinic visits, participants will be discharged from the study.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Omron 907, Omron m7 Intelli, Omron 24/7, Spacelabs 24 hour ABPM, Abbott iStat, Remidio FOP-NM10, Alivecor KardiaMobile 6L, and Tendiomed Arteriograph 24.

Primary outcome(s)

Measured at baseline:

1. Blood pressure measured by 24-hr ABPM, HBPM, and u/aABPM.
2. Left ventricular hypertrophy measured by transthoracic echocardiogram, 12-lead electrocardiogram and smartphone based 6-lead ECG
3. Left ventricular systolic dysfunction assessed transthoracic echocardiogram, and smartphone based 6-lead ECG
4. Hypertensive retinopathy measured using clinical grade retinal camera and smartphone-based portable retinal cameras
5. Renal dysfunction measured using clinical laboratories and point-of-care clinical chemistry devices
6. Arterial stiffness measured using blood-pressure cuff assessment of pressure wave velocity

Key secondary outcome(s)

1. Cardiovascular risk factors assessed using questionnaire at baseline
2. Participant demographics assessed using questionnaire at baseline

Completion date

31/01/2026

Eligibility

Key inclusion criteria

1. Registered in population registers of the KWHDS (The Gambia) or KHDSS (Kenya)
2. Aged ≥ 30 years at the time of enrolment in the study
3. Able to provide written informed consent to participate in the study

Participant type(s)

Healthy volunteer, Population

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

30 years

Upper age limit

120 years

Sex

All

Key exclusion criteria

Pregnant women (self-reported)

Date of first enrolment

01/07/2023

Date of final enrolment

31/12/2024

Locations**Countries of recruitment**

Gambia

Kenya

Study participating centre**KERMI-Wellcome Trust Research Programme**

Center for Geographic Medicine Research, Coast

Kilifi

Kenya

P.O. Box 230-80108

Study participating centre**MRC Unit The Gambia @ LSHTM**

Atlantic Boulevard

Fajara

Gambia

PO Box 273

Sponsor information**Organisation**

London School of Hygiene & Tropical Medicine

ROR

<https://ror.org/00a0jsq62>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

When the results of this study are prepared and published, anonymised data will be made available in line with the policies of the NIHR, LSHTM, KWTRP and MRCG.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1.1	25/01/2023	27/02/2024	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes